Arcus Biosciences Files 8-K: Other Events & Exhibits

Ticker: RCUS · Form: 8-K · Filed: Feb 19, 2025 · CIK: 1724521

Sentiment: neutral

Topics: 8-k, filing, exhibits

TL;DR

Arcus Biosciences filed an 8-K on Feb 19, 2025, reporting 'Other Events' and exhibits.

AI Summary

Arcus Biosciences, Inc. filed an 8-K on February 19, 2025, reporting other events and financial statements/exhibits. The filing date is February 19, 2025, with the earliest event reported on February 18, 2025. The company is incorporated in Delaware and its principal executive offices are located in Hayward, California.

Why It Matters

This 8-K filing indicates that Arcus Biosciences is disclosing material information beyond routine updates, potentially related to significant business events or financial reporting.

Risk Assessment

Risk Level: low — This filing is a standard 8-K for reporting events and exhibits, not indicating any immediate financial distress or significant negative news.

Key Numbers

Key Players & Entities

FAQ

What specific 'Other Events' are being reported by Arcus Biosciences in this 8-K?

The provided text does not detail the specific 'Other Events' beyond stating that this item is being reported.

What is the significance of filing 'Financial Statements and Exhibits' on an 8-K?

Filing financial statements and exhibits on an 8-K typically accompanies significant corporate events or provides updated financial information as required by the SEC.

When was the earliest event reported in this filing?

The earliest event reported in this filing was on February 18, 2025.

Where are Arcus Biosciences' principal executive offices located?

Arcus Biosciences' principal executive offices are located at 3928 Point Eden Way, Hayward, California, 94545.

What is the company's SEC file number?

The company's SEC file number is 001-38419.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on February 19, 2025 regarding Arcus Biosciences, Inc. (RCUS).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing